The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation

Annals of Oncology

Volumn 7, Issue 1, 1996, Pages 83-88

  Mross, K ^a,b   Reifke, J ^a   Bewermeier, P ^a   Kruger W ^a   Hossfeld, D K ^a   Zander, A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Allogeneic bone marrow transplantation; Application schedule; High dose VP 16; Pharmacokinetics; Toxicity

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ETOPOSIDE; METHYLPREDNISOLONE;

ALLERGY; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HUMAN; LEUKEMIA; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030054085     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010486     Document Type: Article

References (30)

1. Zander AR, Culbert S, Jagannath S et al. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. Cancer 1987; 59: 1083-6.
2. Christiansen NP. Allogeneic bone marrow transplantation for the treatment of adult acute leukemias. Hematol Oncol Clin North Am 1993; 7: 177-200.
3. Appelbaum FR, Fisher LD, Thomas ED. Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: A five-year follow-up. Blood 1988; 72:179-84.
4. Michel G. Gluckman E, Esperou-Bourdeau H et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission. J Clin Oncol 1994; 12: 1217-22.
5. Beelen DW, Quabeck K, Graeven U et al. Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen in first remission of acute myeloid leukemia. Blood 1989; 74: 1509-16.
6. Linker C, Ries CA, Damon LE et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81:311-8.
7. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation etoposide versus busulfan cyclophosphamide as preparative regimens for bone marrow transplantation in patients with leukemia who were not in first remission. Blood 1993; 81: 2187-93.
8. Dusenbery KE, Daniels KA, McClure JS et al. Randomized comparison of cyclophosphamide-total body irradiation vs. busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 1995; 31: 119-28.
9. Wolf SN, Grosh WW, Prater K, Hande KR. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 1987; 19: 246-9.
10. Slevin ML, Clark PI, Joel SP et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7:1333-40.
11. Lyding J, Zander A, Wolf J et al. High-dose conditioning regimens with VP-16. In Zander AR, Barlogie B (eds): Autologous Bone Marrow Transplantation for Hodgkin's Disease, Non-Hodgkin's Disease and Multiple Myeloma. Berlin: Springer 1993: 40-7.
12. Bishop JF, Lowenthal RM, Joshua D et al. Etoposide in acute nonlymphocytic leukemia. Blood 1990; 75:27-32.
13. Hande KR. Etoposide pharmacology. Semin Oncol 1992; 19: 3-9.
14. Creger RJ, Fox DRM, Lazerus HM. Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation. Cancer Invest 1990; 8: 13-6.
15. Ehninger G, Proksch B, Schmidt P et al. Unaltered pharmacokinetics after administration of high-dose etoposide without prior dilution. Cancer Chemother Pharmacol 1991; 28:214-6.
16. Schwinghammer TL, Fleming RA, Rosenfeld CS. Disposition of total and unbound etoposide following high-dose therapy. Cancer Chemother Pharmacol 1993; 32: 273-8.
17. Mross K, Bewermeier P, Krüger W et al. Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administration to patients with hematologic malignancies. J Clin Oncol 1994; 12: 1468-74.
18. Rodman JH, Murray DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12:2390-7.
19. Mross K, Bewermeier P, Reifke J et al. Pharmacokinetics of high-dose VP-16: 6-Hour versus 34-hour infusion. BMT 1994; 13: 423-30.
20. Heinzel G, Wolozczak R, Thomann P. Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Stuttgart: Fischer 1993.
21. Bearman SI, Appelbaum FR, Buckner CD et al. Regimenrelated toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-8.
22. Chapuls JC, Keng PC, Sieman DW. Activity of etoposide (VP-16) and teniposide (VM-26) in exponential and plateau-phase human tumor cell cultures. Anti-Cancer Drugs 1992; 3: 245-52.
23. Henwood JM, Brodgen RN. Etoposide. Drugs 1990; 39: 438-90.
24. Slevin ML. The clinical pharmacology of etoposide. Cancer 1991; 67: 319-29.
25. Krüger W, Berger C, Mross K et al. Inhibition of CFU-C growth by VP-16-containing plasma samples obtained from patients after conditioning therapy for bone marrow transplantation. BMT 1995; 14: 9-15.
26. Gibaldi M. Bipharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea & Febiger 1991.
27. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-22.
28. Perry MC. Chemotherapeutic agents and hepatotoxicity. Semin Oncol 1992; 19: 551-65.
29. Rodman JH, Furman WL, Sunderland M et al. Escalting tenisposide systemic exposure to increase dose intensity for pediatric cancer patients. J Clin Oncol 1993; 11: 287-93.
30. Zorsky PE, Perkins JB. Optimizing high-dose therapy using pharmacokinetic principles. Semin Oncol 1993; 20: 2-18. Correspondence to: K. Mross, M.D.